JPWO2020087021A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020087021A5
JPWO2020087021A5 JP2021523041A JP2021523041A JPWO2020087021A5 JP WO2020087021 A5 JPWO2020087021 A5 JP WO2020087021A5 JP 2021523041 A JP2021523041 A JP 2021523041A JP 2021523041 A JP2021523041 A JP 2021523041A JP WO2020087021 A5 JPWO2020087021 A5 JP WO2020087021A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
eye
phentolamine mesylate
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505950A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058182 external-priority patent/WO2020087021A1/en
Publication of JP2022505950A publication Critical patent/JP2022505950A/ja
Publication of JPWO2020087021A5 publication Critical patent/JPWO2020087021A5/ja
Pending legal-status Critical Current

Links

JP2021523041A 2018-10-26 2019-10-25 老眼、散瞳、および他の眼障害の治療のための方法および組成物 Pending JP2022505950A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751391P 2018-10-26 2018-10-26
US62/751,391 2018-10-26
PCT/US2019/058182 WO2020087021A1 (en) 2018-10-26 2019-10-25 Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders

Publications (2)

Publication Number Publication Date
JP2022505950A JP2022505950A (ja) 2022-01-14
JPWO2020087021A5 true JPWO2020087021A5 (zh) 2022-10-31

Family

ID=70330746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523041A Pending JP2022505950A (ja) 2018-10-26 2019-10-25 老眼、散瞳、および他の眼障害の治療のための方法および組成物

Country Status (14)

Country Link
US (5) US11400077B2 (zh)
EP (1) EP3870170A4 (zh)
JP (1) JP2022505950A (zh)
KR (1) KR20210096096A (zh)
CN (1) CN113164452A (zh)
AU (1) AU2019366451A1 (zh)
BR (1) BR112021007725A2 (zh)
CA (1) CA3116589A1 (zh)
IL (1) IL282624A (zh)
MX (1) MX2021004708A (zh)
PH (1) PH12021550882A1 (zh)
SG (1) SG11202104094YA (zh)
WO (1) WO2020087021A1 (zh)
ZA (1) ZA202102488B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2950800B1 (en) 2013-02-01 2020-09-09 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
EP3870170A4 (en) 2018-10-26 2022-07-20 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
US11273141B2 (en) * 2020-05-18 2022-03-15 Vyluma Inc. Low-dose carbachol compositions and methods for treatment of night vision disturbance
WO2022169959A1 (en) * 2021-02-04 2022-08-11 Sydnexis, Inc. Ophthalmic compositions for presbyopia
WO2022226286A1 (en) * 2021-04-23 2022-10-27 Ocuphire Pharma, Inc. Methods and compositions for treating mydriasis, glaucoma, and other ocular conditions
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
US20230263727A1 (en) * 2022-01-14 2023-08-24 Somerset Therapeutics, Llc Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods
US20230248699A1 (en) * 2022-02-09 2023-08-10 Somerset Therapeutics, Llc Formulations of pilocarpine and brimonidine compounds and related methods
CN114796496B (zh) * 2022-05-09 2023-06-23 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 交感神经活化抑制剂和/或α1-肾上腺素能受体抑制剂在制备治疗干眼症的药物中的应用
WO2024048750A1 (ja) * 2022-08-31 2024-03-07 株式会社坪田ラボ α１ブロッカーを含む近視進行抑制用点眼剤

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1094076B (it) 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4443441A (en) 1981-08-07 1984-04-17 Galin Miles A Fixation of intraocular lenses
US4629456A (en) 1981-09-18 1986-12-16 Edwards David L Target ring for an eye dropper bottle
US4515295A (en) 1983-09-06 1985-05-07 St. Luke's Hospital Eye dropper with light source
US4590202A (en) 1984-01-19 1986-05-20 Merck & Co., Inc. N-(2-imidazolidinylidene)-5H-dibenzo[a,d]cyclohepten-5-amine compounds and α2 -adrenergic antagonistic uses thereof
US4659714A (en) 1984-03-27 1987-04-21 Dentsply, Ltd. Anesthetic methods for mammals
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
IE60588B1 (en) 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US4834727A (en) 1987-12-08 1989-05-30 Cope Samuel M Eye dropper bottle attachment for post-surgical and general use
US5261903A (en) 1988-04-11 1993-11-16 M.D. Inc. Composite anesthetic article and method of use
US5149320A (en) 1988-04-11 1992-09-22 Dhaliwal Avtar S Composite anesthetic article and method of use
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5059188A (en) 1990-03-28 1991-10-22 Goddard Larry C Eye dropper attachment
US5192527A (en) 1991-07-01 1993-03-09 Abrahmsohn Glenn M Method of reversing local anesthesia and reagent system therefor
EP0648118A1 (en) 1992-07-02 1995-04-19 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5288759A (en) 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US5514118A (en) 1992-12-23 1996-05-07 Kummer; Frederick J. Measured dose eye dropper
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
CA2201134A1 (en) 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5584823A (en) 1995-07-20 1996-12-17 Ontario Incorporated Illuminated eye dropper device
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
US5627611A (en) 1995-12-29 1997-05-06 Scheiner; Stanley A. Artificial tears
ZA97452B (en) 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6043224A (en) 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
KR100195348B1 (ko) 1996-10-31 1999-06-15 장용택 안정한 프로스타글란딘 e1-함유 주사제 조성물
US5891882A (en) 1996-12-06 1999-04-06 Abbott Laboratories Benzopyranopyrrole and benzopyranopyridine α-1 adenergic compounds
WO1999007353A1 (en) 1997-08-05 1999-02-18 The Mount Sinai School Of Medicine Of The City University Of New York USE OF α1A-ADRENERGIC RECEPTOR ANTAGONISTS IN GLAUCOMA THERAPY
US6001845A (en) 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US5885550A (en) 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
AU7581000A (en) 1999-09-16 2001-04-17 Gerald D. Horn A method for optimizing pupil size using alpha antagonist
US6420407B1 (en) * 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US20020082288A1 (en) 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
US6730065B1 (en) 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
AU2001259848B2 (en) 2000-05-12 2005-10-13 Septodont Holding Sas Local anesthetic methods and kits
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US20060211753A1 (en) 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US6515006B2 (en) * 2000-11-08 2003-02-04 Hmt Pharma, Inc. Ophthalmic formulation which modulates dilation
US7229630B2 (en) 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US20030236306A1 (en) 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
WO2006041875A1 (en) 2004-10-06 2006-04-20 Allergan, Inc. Novel prostamides for the treatment of glaucoma and related diseases
WO2006083841A2 (en) 2005-02-01 2006-08-10 Allergan, Inc. Therapeutic esters
US20060257388A1 (en) 2005-05-13 2006-11-16 Julius Knowles Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
WO2007008666A2 (en) 2005-07-08 2007-01-18 Ocularis Pharma, Inc. Compositions and methods for improving vision using adherent thin films
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CA2657481A1 (en) 2006-07-21 2008-01-24 Queen's University At Kingston Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US20090131303A1 (en) 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
US20090220618A1 (en) 2008-02-29 2009-09-03 Erning Xia Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide
CN101959500A (zh) 2008-03-17 2011-01-26 爱尔康研究有限公司 包含硼酸类化合物-多元醇络合物的水性药物组合物
US8080550B2 (en) 2008-08-01 2011-12-20 Alpha Synergy Development, Inc. Anesthetic compositions and methods of use
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
US20130143938A1 (en) 2009-07-27 2013-06-06 Eye Therapies Llc Compositions and Methods for the Treatment of Migraine
US20110178147A1 (en) 2009-10-20 2011-07-21 Allergan, Inc. Compositions and methods for controlling pupil dilation
EP2491017B1 (en) 2009-10-21 2014-08-27 Allergan, Inc. Alpha adrenergic receptor modulators
ES2618907T3 (es) 2010-12-03 2017-06-22 Allergan, Inc. Composiciones farmacéuticas en crema que comprenden oximetazolina
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20130172357A1 (en) 2011-02-03 2013-07-04 Eye Therapies Llc Compositions and Methods for Treatment of Glaucoma
RU2648439C2 (ru) 2011-02-15 2018-03-26 Аллерган, Инк. Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
EP2680816A1 (en) 2011-03-03 2014-01-08 Allergan, Inc. Non-aqueous silicone-based ophthalmic formulations
US20120277239A1 (en) 2011-04-28 2012-11-01 Alpha Synergy Development Inc. Compositions and Methods for Improving Night Vision
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
CA2863760A1 (en) 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
EP2819674A2 (en) 2012-02-27 2015-01-07 Eye Therapies LLC Compositions and methods for the treatment of migraine
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
AU2013201465B2 (en) * 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
DK2950648T3 (da) 2013-02-01 2019-12-02 Ocuphire Pharma Inc Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf
EP2950800B1 (en) 2013-02-01 2020-09-09 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
US8597629B1 (en) 2013-06-21 2013-12-03 Premium Ocular Solutions LLC. Artificial tear compositions comprising a combination of nonionic surfactants
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
KR102472774B1 (ko) 2016-08-19 2022-11-30 오라시스 파마슈티칼스 엘티디. 안과용 약학 조성물 및 이와 관련된 용도
MX2020011301A (es) 2018-04-24 2021-01-29 Allergan Inc Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares.
EP3870170A4 (en) 2018-10-26 2022-07-20 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES

Similar Documents

Publication Publication Date Title
US5459133A (en) Methods and products for treating presbyopia
JP2023103400A (ja) 老視を治療するための組成物及び方法
EP3031457B1 (en) Medicament comprising pilocarpine and brimonidine
AU754588B2 (en) Cholinergic agents in the treatment of presbyopia
EP3681500B1 (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
JP7359204B2 (ja) Ｎｉｔｍを予防及び治療するための医薬組成物及びその医薬用途
JPWO2020087021A5 (zh)
WO2022228546A1 (zh) 用于治疗近视的方法和药物组合物
KR101723703B1 (ko) 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물
EP0478694A1 (en) TREATMENT AND REGULATION OF EYE DEVELOPMENT.
KR102633606B1 (ko) 활성 성분으로서 티오트로피움을 포함하는, 근시 예방, 근시 치료, 및/또는 근시 진행 예방을 위한 제제
CN111787920A (zh) 用于控制和/或降低近视发展的药物组合物
AU2022314016B2 (en) Method for treating myopia with vinpocetine
US20210353584A1 (en) Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance
Milton Pr IOPIDINE®
WO2022249069A1 (en) Low-dose carbachol ophthalmic compositions with cumulative effect
CN118236372A (zh) 治疗近视的药物和方法
KR20000013487A (ko) 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물
Hydrochloride et al. Public Assessment Report Paediatric data